196 related articles for article (PubMed ID: 11449871)
1. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
2. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
4. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab.
Williamson TS
Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
[No Abstract] [Full Text] [Related]
6. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Hadj Tahar A
Issues Emerg Health Technol; 2005 Mar; (66):1-4. PubMed ID: 15806747
[TBL] [Abstract][Full Text] [Related]
7. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
8. Campath-1H for chronic lymphocytic leukemia.
Rai KR
Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
[No Abstract] [Full Text] [Related]
9. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
Tam CS
Leuk Lymphoma; 2009 Oct; 50(10):1557-8. PubMed ID: 19757304
[No Abstract] [Full Text] [Related]
10. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
Osterborg A; Mellstedt H; Keating M
Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
[TBL] [Abstract][Full Text] [Related]
13. Berlex Laboratories to market new treatment for B-CLL.
Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
[No Abstract] [Full Text] [Related]
14. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.
Kunz JS; Bannerji R
Leuk Lymphoma; 2005 Apr; 46(4):635-7. PubMed ID: 16019499
[No Abstract] [Full Text] [Related]
15. Alemtuzumab for treatment of lymphoproliferative disorders.
Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
[No Abstract] [Full Text] [Related]
16. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
Zent CS
Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
[No Abstract] [Full Text] [Related]
17. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman M
J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616
[No Abstract] [Full Text] [Related]
20. Nursing care of patients receiving Campath.
Seeley K; DeMeyer E
Clin J Oncol Nurs; 2002; 6(3):138-43. PubMed ID: 11998606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]